Collaboration Agreement: Lineage Cell Therapeutics entered a collaboration and license agreement with Genentech and Roche in December 2021 to develop OpRegen for ocular disorders, particularly geographic atrophy due to age-related macular degeneration.
Clinical Trial Progress: OpRegen is currently undergoing a Phase 2a clinical trial named "GAlette," focusing on patients with geographic atrophy secondary to AMD.
Milestone Achievement: On November 20, 2025, Lineage achieved a significant development milestone under the Roche Agreement, leading to a $5 million payment.
Payment Distribution: Approximately 24.1% and 21.5% of the milestone payment will be allocated to the Israel Innovation Authority and Hadasit Medical Research and Development, respectively, in accordance with relevant laws and agreements.
Wall Street analysts forecast LCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LCTX is 4.50 USD with a low forecast of 3.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast LCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LCTX is 4.50 USD with a low forecast of 3.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.650
Low
3.00
Averages
4.50
High
9.00
Current: 1.650
Low
3.00
Averages
4.50
High
9.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$9
2025-11-24
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$9
AI Analysis
2025-11-24
maintain
Buy
Reason
H.C. Wainwright reiterated a Buy rating and $9 price target on Lineage Cell Therapeutics (LCTX), saying the major breakout event the firm is looking for is visibility out of global partner Roche (RHHBY) regarding OpRegen data and next steps. Monday's $5M milestone represents yet another tangible piece of evidence for Roche's progress in the OpRegen program for which they have global rights for dry-AMD and geographic atrophy, the analyst tells investors in a research note. The firm added that data, anecdotes, and comps provide significant support that OpRegen is moving into later studies in Roche's hands.
B. Riley Securities
Mayank Mamtani
Strong Buy
Maintains
$4 → $3
2025-03-14
Reason
B. Riley Securities
Mayank Mamtani
Price Target
$4 → $3
2025-03-14
Maintains
Strong Buy
Reason
B. Riley analyst Mayank Mamtani lowered the firm's price target on Lineage Cell Therapeutics (LCTX) to $3 from $4 and keeps a Buy rating on the shares. Lineage Cell Therapeutics' Q4 recap focused on Roche (RHHBY)-partnered OpRegen program, steadily advancing earlier-stage wholly-owned programs, and Lineage's dominant position in large-scale allogeneic manufacturing to produce millions of retinal pigment epithelium cells, the analyst tells investors in a research note. The OpRegen dry AMD opportunity could come through the ongoing Phase II GAlette study interim data release, and Roche opting to progress to a randomized controlled study to confirm high efficacy benefits noted with optimized delivery system in sizeable patient population, the firm says.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LCTX
Unlock Now
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$9
2025-03-11
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$9
2025-03-11
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$2
2025-03-11
Reason
D. Boral Capital
Jason Kolbert
Price Target
$2
2025-03-11
Maintains
Strong Buy
Reason
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological and ophthalmic conditions. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
